DICE News and Press, DICE Therapeutics Inc. From 11/16/21

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

DICE Therapeutics (NASDAQ:DICE): Q3 GAAP EPS of -$2.30. Cash and cash equivalents and marketable securities totaled $335.7M Press Release For further details see: DICE Therapeutics reports Q3 results

Dosed first healthy volunteers in Phase 1 clinical trial of oral IL-17 antagonist S011806 Successfully completed $234.6 million upsized initial public offering SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceuti...

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

Gainers: Sesen Bio SESN +29%. Cipher Mining CIFR +25%. Radius Health RDUS +24%. Valneva (NASDAQ:VALN) +18%. Canaan CAN +18%. Olema OLMA +18%. ContextLogic (NASDAQ:WISH) +17%. Puhui Wealth Investment Management (NASDAQ:PHCF) +16%. Permian Basin Royalty Trust (NYSE:PBT)...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

The IPO market was full steam ahead this past week as 11 IPOs came to market. SPAC activity remained steady with seven blank check IPOs. New filers continue to pour into the IPO pipeline, with 15 IPOs and eight SPACs submitting initial filings. For further details see: U...